GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Forward PE Ratio

Bright Minds Biosciences (Bright Minds Biosciences) Forward PE Ratio : 0.00 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Forward PE Ratio?

Bright Minds Biosciences's Forward PE Ratio for today is 0.00.

Bright Minds Biosciences's PE Ratio without NRI for today is 0.00.

Bright Minds Biosciences's PE Ratio for today is 0.00.


Bright Minds Biosciences Forward PE Ratio Historical Data

The historical data trend for Bright Minds Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Forward PE Ratio Chart

Bright Minds Biosciences Annual Data
Trend
Forward PE Ratio

Bright Minds Biosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Bright Minds Biosciences's Forward PE Ratio

For the Biotechnology subindustry, Bright Minds Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Forward PE Ratio falls into.



Bright Minds Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Bright Minds Biosciences  (NAS:DRUG) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Bright Minds Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences (Bright Minds Biosciences) Headlines